Results 31 to 40 of about 949 (151)

Role of Saroglitazar in Non Diabetic Non Alcoholic Fatty Liver Disease Patients: A Retrospective Observational Study [PDF]

Journal of Clinical and Diagnostic Research, 2021
Introduction: Non Alcoholic Fatty Liver Disease (NAFLD) is a commonly encountered problem which affects one third of the general population. Saroglitazar, a Peroxisome Proliferator Activated Receptor (PPAR) alpha α and gamma γ agonist has been ...
Akash Jaiswal, Kavita Jain, Amit Kumar Singh   +2 more
doaj   +1 more source

Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2mg on total cholesterol (mg/dL).

, 2022
Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2mg on total cholesterol (mg/dL).
Manik Chhabra (10822587), Kota Vidyasagar (10822584), Muhammed Rashid (10822590), Rishabh Sharma (6505124), Sai Krishna Gudi (12559618), Jatin Sharma (7408166)   +5 more
core   +1 more source

Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2mg on LDL-cholesterol (mg/dL).

, 2022
Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2mg on LDL-cholesterol (mg/dL).
Manik Chhabra (10822587), Kota Vidyasagar (10822584), Muhammed Rashid (10822590), Rishabh Sharma (6505124), Sai Krishna Gudi (12559618), Jatin Sharma (7408166)   +5 more
core   +1 more source

Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2 mg on serum creatinine (mg/dL).

, 2022
Forest plot of comparison of saroglitazar 4mg versus saroglitazar 2 mg on serum creatinine (mg/dL).
Manik Chhabra (10822587), Kota Vidyasagar (10822584), Muhammed Rashid (10822590), Rishabh Sharma (6505124), Sai Krishna Gudi (12559618), Jatin Sharma (7408166)   +5 more
core   +1 more source

Effect of saroglitazar and pioglitazone on lipid parameters and glycemic profile in type II diabetes mellitus patients with dyslipidemia: An observational open-label study

National Journal of Physiology, Pharmacy and Pharmacology, 2021
Background: Diabetes mellitus when associated with dyslipidemia poses a different direction of management. For this subgroup of patients, we need stricter and different approach to improve treatment outcome and overall benefit.
Vidhya Sreekumar, Dayanidhi Meher, Siddhartha Goutam, Manas Ranjan Mishra, Ratikanta Tripathy, Jyotirmoyee Jena   +5 more
doaj   +1 more source

To evaluate the safety and efficacy of saroglitazar among pre-diabetes and dyslipidemia [PDF]

, 2022
Patients with prediabetes are not only at increased risk of progression to type 2 diabetes, but they are also at high risk of developing cardiovascular (CV) risk compared to normoglycemic people.
Dhone, Pravin G., Behera, Desabandhu, Mubeen, Mohd. Faheem, Gupta, Vikas   +3 more
core   +1 more source

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease

Biomolecules, 2023
The number of patients with nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is increasing globally and is raising serious concerns regarding the increasing medical and economic burden incurred for their treatment.
Shotaro Kamata, Akihiro Honda, Isao Ishii   +2 more
doaj   +1 more source

Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis

, 2022
Saroglitazar is a novel peroxisome proliferator-activated receptor (PPAR) agonist with dual agonistic properties (α/γ). Due to a strong mechanistic rationale, we aimed to test the safety and efficacy of saroglitazar in patients with primary biliary ...
Pyrsopoulos, Nikolaos, Parmar, Deven V, Levy, Cynthia, Rossi, Simona, Chalasani, Naga P, Caldwell, Stephen H, Vuppalanchi, Raj, Shaikh, Farheen, Goldberg, David S, Bainbridge, James D, deLemos, Andrew S, Sheikh, Aasim, Mena, Edward A, Ravinuthala, Ravi   +13 more
core   +1 more source

Saroglitazar suppresses KIM-1 and type IV collagen in high fat diet and low-dose streptozotocin-induced diabetic nephropathy in Wistar rats [PDF]

Iranian Journal of Basic Medical Sciences
Objective(s): Nephropathy is the most common comorbidity linked to T2D. The present study aimed to examine the potential of saroglitazar in the context of a high-fat diet and low-dose streptozotocin-induced diabetic nephropathy in Wistar rats.
Rizwan Ahamad, Uma Bhandari, Sayima Nabi, Shweta Sharma   +3 more
doaj   +1 more source

Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

Cardiovascular Diabetology, 2020
Background The potential for PPAR agonists to positively affect risk of cardiovascular disease in patients with type 2 diabetes (T2DM) is of persistent attention.
Manjunath Krishnappa, Kishor Patil, Krupi Parmar, Purav Trivedi, Nirali Mody, Chintan Shah, Khushboo Faldu, Sanjay Maroo, for the PRESS XII study group, Deven Parmar   +9 more
doaj   +1 more source